Business Context and Reporting Period
This Form 8-K Current Report was filed by Nuvation Bio Inc. on October 7, 2024. The filing discloses a significant executive appointment effective as of the report date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation and appointment details rather than financial performance.
Material Changes
The primary material change is the appointment of Philippe Sauvage as Chief Financial Officer and Principal Financial Officer, effective October 7, 2024. Mr. Sauvage joins the company from Sanofi, where he served as Senior Vice President, Global Head of Operations and Access.
Management Commentary and Compensation Terms
The Compensation Committee approved an employment agreement with the following terms:
- Base Salary: $510,000 annually.
- Bonus: Discretionary annual bonus of up to 45% of the base salary.
- Equity: Option to purchase 750,000 shares of common stock. Vesting schedule includes 25% on the one-year anniversary and the remainder monthly thereafter (1/48th per month).
- Severance: Involuntary termination without cause triggers 12 months of base salary and 12 months of COBRA reimbursement.
- Change in Control: Termination within 12 months of a change in control triggers the standard severance plus 100% of the target annual bonus and full acceleration of time-based equity vesting.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the 750,000 stock options granted to the new CFO.
- Review the company's cash position to assess the impact of the new executive compensation package on liquidity.
- Confirm the absence of any undisclosed family relationships or conflicts of interest involving the new appointee.
- Monitor future filings for the departure of the previous CFO, if applicable, to understand the transition timeline.